Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ethambutol and intra-ocular pressure.

P R Pattisson, O J Kun, A I Friedmann

    Tubercle
    |March 1, 1978
    PubMed
    Summary

    This study found that ethambutol, used in tuberculosis treatment at a mean dosage of 14.4 mg/kg, did not cause ocular toxicity or affect intra-ocular pressure in Korean patients. Ophthalmological assessments confirmed safety in the studied dosage range.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    PRION-1 scales analysis supports use of functional outcome measures in prion disease.

    Neurology·2011
    Same author

    Visual field examination.

    Journal of the Royal Society of Medicine·2010
    Same author

    Visual field examination.

    Proceedings of the Royal Society of Medicine·2010
    Same author

    Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.

    Lancet (London, England)·2010
    Same author

    Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.

    HIV medicine·2010
    Same author

    Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

    Lancet (London, England)·2009

    Area of Science:

    • Ophthalmology
    • Pharmacology
    • Infectious Diseases

    Background:

    • Tuberculosis (TB) treatment often involves ethambutol.
    • Potential ocular side effects of ethambutol necessitate careful monitoring.
    • Understanding ethambutol's impact on intra-ocular pressure (IOP) is crucial for patient safety.

    Purpose of the Study:

    • To evaluate the ocular toxicity of ethambutol in Korean patients with tuberculosis.
    • To determine if ethambutol, at a mean dosage of 14.4 mg/kg, affects intra-ocular pressure.

    Main Methods:

    • A pair-matched study design comparing patients receiving ethambutol with those on other anti-TB chemotherapy.
    • Comprehensive ophthalmological assessments including fundi examination, visual fields, and macular thresholds.
    • Measurement of intra-ocular pressures before and after a water-drinking test, with the ophthalmologist blinded to treatment allocation.

    Main Results:

    • No evidence of ocular toxicity was observed in the ethambutol group.
    • Ethambutol, at the studied dosage, did not demonstrate a significant effect on intra-ocular pressure.
    • The water-drinking test results were consistent across both treatment groups.

    Conclusions:

    • Ethambutol is safe regarding ocular toxicity and IOP at a mean dosage of 14.4 mg/kg in Korean TB patients.
    • Routine ophthalmological assessments are important for TB patients undergoing ethambutol therapy.
    • Further research may explore long-term effects or higher dosages of ethambutol.

    Related Experiment Videos